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Abstract
Background: In prognostic terms, evaluation of an ECG recording in acute myocardial
infarction (AMI) appears to be inferior to echocardiographic (ECHO) assessment of left ven-
tricular remodelling and the activities of cardiac enzymes and certain hormones. It was our
hypothesis that, in the era of interventional treatment of AMI, some ECG parameters are still
valid for the purpose of risk stratification.
Methods: A total of 66 consecutive patients with AMI (43 male and 23 female, with a mean
age of 61 ± 11 years) were treated with primary percutaneous coronary intervention (PCI). In
each patient ECG and ECHO examinations were performed within 5–7 days of admission for
the detection of left ventricular hypertrophy (LVH). In further analysis the following ECG-
-based LVH parameters were taken into consideration: Sokolov-Lyon voltage duration (SLVd),
Cornell voltage duration CVd), 12-lead QRS voltage duration (12QRSVd), their product with
QRS duration and an ECG index of left ventricular mass (LVMIECG). Patients were followed
for 6 months. The combined end-point included death, infarction, a need for prompt coronary
intervention and hospitalization for heart failure.
Results: The combined end-point was observed in 16 patients (24.2%). Survival analysis
revealed that the most important prognostic factors were associated with a prolongation of the
QRS duration. Increased SLVd was found in 43% of the patients with events compared to
14% in those without them (p < 0.01), CVd in 43% vs. 12% (p < 0.05), 12QRSVd in 81%
vs. 44% (p < 0.05) and LVMIECG in 75% vs. 26%, p < 0.001). There was no evidence for
a difference in Cornell voltage. Univariate logistic regression indicated a 4-fold to 8-fold
increase in the risk of events associated with abnormal SLV, SLVd or LVMIECG. Multivariate
Cox analysis showed that the LVH presence in the ECG, defined as an increased SLVd product
or increased LVMIECG, was an independent predictor of cardiovascular events after AMI.
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disturbances, implanted cardiac stimulator or an
inadequate echocardiographic window) or who suf-
fered from an illness which might limit short-term
(6-month) survival were excluded. The clinical char-
acteristics of the patients are given in Table 1.
Left ventricular hypertrophy
detection on ECG
Routine 12-lead surface ECGs (ECG, GE Med-
ical Systems, CASE v.4.1) were recorded before
hospital discharge (usually 5–7 days after the coro-
nary intervention) for all the patients in order to
determine left ventricular mass (LVMECG) and the
presence of LVHECG features. The median cardiac
cycle complexes were collected automatically and
displayed on a screen using the magnifying func-
tion with a gain of up to 8 cm/1 mV and a paper speed
of 200 mm/s. The QRS complex parameters were
measured manually with a calliper to the nearest
1 ms and voltage was measured to the nearest 4 mV.
All measurements were performed in accordance
with the Common Standards in Electrocardiography
Working Party recommendations [13] by an expe-
rienced investigator (MS) who had no knowledge
of the patients’ clinical data and echocardiographic
findings. The following ECG variables and indices
were obtained from 12 simultaneously recorded
leads: QRS complex duration (QRSd, ms), average
12-lead time to maximal deflection (TMD, ms),
average 12-lead QRS complex voltage (12QRSV, mV),
calculated as a sum of absolute voltages of all de-
flections within 12 QRS complexes divided by the
number of leads, and the average product of 12-lead
QRS voltage and duration (12QRSVd, mV/ms).
Commonly recommended ECG criteria were also
calculated: Sokolov-Lyon voltage (SLV, mV) as
a sum of the S-wave voltage in the V1 or V2 leads and
the R-wave voltage in V5 or V6 (whichever higher),
Cornell voltage (CV, mV) as a sum of the R-wave
voltage in the aVL lead and the S-wave voltage in
the V3 lead. A correction for female gender was
made by adding 0.6 mV to the calculated CV. Their
voltage-duration products (SLVd and CVd) were
also calculated [14–16].
The LVMECG was calculated by analogy to
echocardiographically-determined LVM, according
Conclusions: In the era of interventional treatment of AMI, the ECG features of left ventricular
hypertrophy carry independent significant prognostic information. (Cardiol J 2007; 14: 347–354)
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Introduction
The prognostic use of routine electrocardio-
gram (ECG) in patients with an acute myocardial in-
farction (AMI) currently appears to have been su-
perseded by biochemical markers and echocardio-
graphic data [1], despite the large body of evidence
accumulated over decades indicating that many ECG
variables carry information about in-hospital and
long-term outcome [2–6]. Early studies indicated
a greater threat to patients who presented with
Q-wave infarction [2], a greater QRS score [3, 4],
a slow ST-segment resolution rate [5, 6], prolonged
QT and increased QT dispersion [7, 8] or sustained
T-wave abnormalities [9].
In many of these studies, however, the pres-
ence of left ventricular hypertrophy (LVH) was
deemed to be an exclusion criterion, despite the fact
that LVH was found to be a factor multiplying the
risk for subsequent events in the AMI-patient pop-
ulation [10–12]. In fact, these studies were conduct-
ed before the advance of myocardial reperfusion
techniques. Thus the significance of the presence
of LVH requires verification in AMI-patients treat-
ed with the percutaneous coronary interventions
(PCI) currently commonly applied. Accordingly, we
undertook this study to solve the question of wheth-
er ECG-based LVH detection might be helpful in
distinguishing AMI-patients at high risk of an unfa-
vourable outcome.
Method
Study population
A total of 66 consecutive patients with ST-ele-
vation acute myocardial infarction (STEMI) treat-
ed by means of direct coronary stenting were in-
cluded in the study. There were 43 males and
23 females with a mean age of 61 ± 11 years. They
entered the study if the following inclusion criteria
were met: first STEMI, successful coronary stent-
ing (TIMI coronary flow grade 3 after intervention),
uncomplicated in-hospital stay, stable sinus rhythm
and the granting of informed consent. Patients who
needed circulatory support, with conditions that
limited LVH detection (intraventricular conduction
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echocardiographer (BK) blind to other data. LV anato-
my and function were assessed in accordance with
current American Society of Echocardiography recom-
mendations [18] to obtain the following parameters:
— LV diastolic and systolic diameter, and inferi-
or LV wall and interventricular septum thick-
ness from the left parasternal long-axis view
(all in centimetres);
— LV ejection fraction, calculated according to
Simpson’s rule obtained from an apical four-
chamber view (%),
to the following formula: LVMECG={[(2TMD) +
+(QRSD/p)3 – (QRSD/p)3]}¥0.0001 [ms3], and in-
dexed to body surface area (BSA), providing the
LVMIECG as [LVMECG/BSA, ms3/m2], introduced by
the authors and described in detail elsewhere [17].
Left ventricular hypertrophy
detection on ECHO
Transthoracic echocardiographic examinations
[Sonos 2500, Hewlett-Packard] were performed on all
the patients on the same day by an experienced
Table 1. Clinical characteristics of the study group.
Parameter All patients (n = 66) With event (n = 16) Event-free (n = 50)
Age (years)# 61 ± 10 68 ± 9 59 ± 10
Sex (male) 43 (65)  8 (50) 35 (70)
Body mass index [kg/m2] 27.1 ± 4.0 27.1 ± 3.3 27.1 ± 4.2
Obesity (BMI > 30 kg/m2) 13 (20)  4 (25) 8 (16)
Risk factors
Smoking (current or in the past) 47 (71) 11 (69) 36 (72)
Hyperlipidemia 49 (74) 12 (75) 37 (74)
Arterial hypertension 39 (59) 12 (75) 27 (54)
Diabetes mellitus or OGI 16 (24) 6 (38) 10 (20)
Family history 16 (24) 4 (25) 12 (24)
STEMI characteristics
Location:
anterior 21 (31) 7 (44) 14 (28)
inferior 38 (58) 8 (50) 30 (60)
other 7 (11) 1 (6)  6 (12)
Infarct-related artery:
LAD/Diag1 18 (27) 7 (44) 11 (22)
RCA 31 (47) 7 (44) 24 (48)
LCx/OM 17 (26) 2 (8) 15 (30)
Killip class > II* 6 (9) 4 (9)  2 (4)
Systolic blood pressure [mm Hg] 119 ± 17 112 ± 24 122 ± 14
Heart rate [bpm] 72 ± 11 76 ± 13 71 ± 10
Echocardiographic data (at discharge)
LVEF [%] 47 ± 9 48 ± 9 47 ± 9
LVEF < 40% 9 (13) 2 (13) 7 (14)
LVEDD [cm] 5.1 ± 0.6 5.3 ± 0.7 5.0 ± 0.5
LVEDD > 5.5 cm 13 (20)  5 (31)  8 (16)
LVMI [g/m2]§ 105.1 ± 24.1 122.7 ± 30.2 99.4 ± 18.8
LVMI > UNL 16 (24)  6 (38) 10 (20)
Medications (at discharge)**
Beta-blocker 61 (92) 14 (88) 47 (96)
ACEI and/or ARB 64 (96) 15 (94) 49 (98)
Antiarrhythmics 5 ( 8)  3 (19) 2 (4)
SD — standard deviation, OGI — oral glucose intolerance, STEMI — ST-segment elevation acute myocardial infarction, LAD — left anterior descend-
ent branch of the left coronary artery, Diag — diagonal branch of the LAD, RCA — right coronary artery, LCx — left circumflex branch of the left coro-
nary artery, OM — obtuse marginal branch of the LCx, LVEF — left ventricular ejection fraction, LVEDD – left ventricular end-diastolic diameter,
LVMI — index of the left ventricular mass, UNL — upper normal limit, ACEI — angiotensin converting-enzyme inhibitor, ARB — angiotensin AT1-receptor
inhibitor; **other medications (aspirin, statins) were administered to all patients. Data presented as mean ± 1 SD or number (%) as appropriate.
Statistics: discrete data were compared using Student’s t test for unpaired comparisons, numerical data were compared using the two-sided Fisher
exact test. *p < 0.05, #p < 0.01, §p < 0.001 — significance of the difference between patients with and without an event
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— LVMECHO, calculated according to the correct-
ed ASE-cube formula [18]: LVM [g] = 0.8 [1.04
{(LVEDD + IVSThd + LVPWThd)3 –
–LVEDD3} + 0.6, and indexed for BSA (LVMIECHO).
LVH was diagnosed if LVMIECHO exceeded 117
g/m2 in men and 104 g/m2 in women [19].
Follow-up
Patients were observed for a period of 6 months.
The following events were noticed: death (for any
reason), myocardial infarction, a need for urgent cor-
onary intervention, hospitalization for heart failure
or a cerebrovascular event. The above-listed crite-
ria constituted a combined end-point of the study.
Statistics
Numerical data are presented as means + 1 SD,
while categorical data are given as number and per-
centage, as appropriate. Between-group compari-
sons were made using the Kolmogorov-Smirnov
test. Proportions were tested by means of the Fish-
er exact test. Between-variable correlations were
tested by means of the Pearson-moment correla-
tion analysis. Test accuracy was compared using
ROC curve analysis. Logistic regression analysis
was used to identify a significant association be-
tween the variables analysed and event occurrence.
Cox regression hazard analysis was used to identify
independent predictors. For all tests a p-value
< 0.05 was considered significant.
Results
The combined end-point was noticed in 16 pa-
tients (24.2%). There was no death during the
6-month follow-up. Other events observed were as
follows: recurrent myocardial infarction in one patient,
unstable angina with a need for coronary intervention
(either percutaneous or surgical) in 8 patients, neu-
rological complications in 4 patients and heart failure
development in 3 patients. ECG features depending
on outcome are presented in Table 2, in general ECG
variables that are considered to reflect LVM and form
the basis for LVH in clinical settings. Among these,
the most significant differences between patients with
and without an unfavourable outcome in this respect
were found for the time-dependent variables.
On the basis of the receiver-operator curve func-
tion the following cut-off values of the ECG LVH
descriptors were further used: SLV > 3.4 mV,
SLVd > 343.7 mV/ms, CV > 2.2 mV, CVd > 260 mV/ms,
12QRS voltage > 1.23 mV, 12QRS voltage/duration
product > 123 mV/ms and LVMIECG > 115 ms3/m2.
The proportion of events associated with different
ECG criteria is given in Table 3, while their statisti-
cal performance in presented in Table 4. For a given
cut-off value a different event rate was observed. The
concordance of the applied ECG criteria with
echocardiographically-determined LVH is present-
ed in Figure 1. Correlations between certain ECG
variables and LVMI determined echocardiographi-
cally are presented in Figure 2.
The results of univariate logistic regression
analysis indicated that the LVH ECG features most
predictive for an unfavourable outcome were SLVd
product and LVMIECG (Table 5). This model allowed
90% of patients to be classified as without events
and 50% as patients with events. Both SLVd product
and LVMIECG appeared as predictors of cardiovas-
cular events independently of age and LV function
Table 2. ECG left ventricular mass determinants depending on outcome.
Parameter With event (n = 16) Without event (n = 50) Significance*
Heart rate [bpm] 71 ± 9 72 ± 12 NS
QRS duration [ms] 109 ± 10 102 ± 6 < 0.001
QTc max [ms] 463 ± 28 446 ± 32 NS
QT dispersion [ms] 32 ± 10 29 ± 11 NS
SL voltage [mV] 3.30 ± 1.22 2.51 ± 0.83 < 0.05
SL v/d [mV/ms] 364 ± 148 258 ± 90 < 0.05
Cornell voltage [mV] 2.12 ± 0.83 1.94 ± 0.59 NS
Cornell v/d [mV/ms] 233 ± 99 199 ± 61 NS
12QRS voltage [ìV] 1.46 ± 0.36 1.21 ± 0.30 NS
12QRS v/d [mV/ms] 160 ± 45 123 ± 34 < 0.05
LVMECG [ms3] 252 ± 81 194 ± 49 < 0.01
LVMIECG [ms3/m2] 134 ± 41 105 ± 26 < 0.005
SL — Sokolov-Lyon index, 12QRS — the average of 12-lead QRS, LVM — left ventricular mass, v/d — voltage-duration product; *Kolmogorov-
-Smirnov test
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Figure 1. Concordance between ECG variables and
echocardiographically-determined left ventricular hy-
pertrophy (LVH). Bars represent the proportion of posi-
tive and negative LVH on ECG and echocardiography.
Abbreviations: see “Method” section; *p < 0.05, **p <
0.01, ***p < 0.001, two-sided Fisher exact test.
Figure 2. Coefficients of correlation between ECG varia-
bles and echocardiographically-determined LV mass in-
dex. Bars represent Pearson moment coefficients of
correlation between a given ECG parameter and left
ventricular mass index value. Abbreviations: see “Me-
thod” section; *p < 0.05, **p < 0.01, ***p < 0.001.
Table 3. Proportion of events depending on ECG variables.
Variable Events (n = 16) No events (n = 50) p*
SL voltage > 3.4 8 (50) 8 (16) 0.0014
SL v/d > 343.7 9 (43) 7 (14) 0.0015
Cornell voltage > 2.2 9 (56) 14 (28) 0.0682
Cornell v/d > 260 7 (43) 6 (12) 0.0104
12QRS voltage > 1.23 12 (75) 21 (42) 0.0424
12QRS v/d > 123 13 (81) 22 (44) 0.0109
LVMIECG > 115 12 (75) 13 (26) 0.0008
*Fisher’s exact test (2-sided). Cut-off values of ECG variables as determined on the basis of ROC curve analysis. Abbreviations: see Table 2.
Table 4. Statistical performance of ECG variables in the prediction of events.
Variable Sensitivity Specificity PPV NPV RR
S-L voltage > 3.4 61.5 84.9 50.0 90.0 3.1
S-L v/d > 343.7 56.2 86.0 56.2 86.0 3.1
Cornell voltage > 2.2 39.3 83.7 56.2 72.0 2.0
Cornell v/d > 260 53.8 83.0 43.8 88.0 3.6
12QRS voltage > 1.23 36.4 87.9 75.0 58.0 1.8
12QRS v/d > 123 37.1 90.3 81.3 56.0 1.8
LVMIECG > 115 48.0 90.2 75.0 74.0 2.9
PPV — positive predictive value, NPV — negative predictive value, RR — risk ratio. Other abbreviations: see Table 2.
Table 5. Univariate logistic stepwise regression for the ECG variables examined and cardiovascular
events during follow-up.
Variable Odds ratio for event (95% CI) p
S-L voltage-duration product 5.70 (1.43–22.68) 0.0134
Left ventricular mass index (ECG) 1.02 (1.00–1.04) 0.0413
Other ECG parameters did not enter the model.
352
Cardiology Journal 2007, Vol. 14, No. 4
www.cardiologyjournal.org
assessed echocardiographically. The respective
hazard ratios are presented in Table 6.
Discussion
Main findings
In the present study we showed that ECG
features of increased LVM, albeit only moderately
sensitive, were independently associated with
a clinical outcome over a 6-month period in PCI-
-treated patients with STEMI. We found the
“classical” voltage LVH criteria to be of limited
value in these patients. Taking QRSd into account
meaningfully improved their statistical perform-
ance. Interestingly, a voltage-independent
LVMI, proposed by the authors [17], which de-
scribes abstract time conditions [m3] that are re-
quired for the entire cardiac muscle to be depo-
larized, was not found to be inferior to the SLVd
product and appeared as a predictor of risk in-
dependently of age and LV ejection fraction. The
authors previously found that LVMIECG signifi-
cantly correlated with LVM estimated echocardi-
ographically [17].
Left ventricular hypertrophy
and post-AMI prognosis
Almost 30 years ago Pohjola et al. [20] noticed
that the presence of abnormal P terminal force was
associated with a 4.7 times greater risk of mortal-
ity in a large cohort of patients with AMI over
a 5-year follow-up. Although the authors considered
the P-wave terminal force of –0.03 mm/ms or
greater to be a feature of heart failure, one has to
acknowledge that the same ECG pattern had been
treated over decades as one of the early signs of
LVH and was thus included in various LVH point-
scores [21]. Several studies brought proof of a sig-
nificant association between LVH on ECG and
short-term and long-term post-myocardial infarc-
tion mortality in large cohorts of fibrinolyzed pa-
tients with either ST-elevation or non-ST-elevation
AMI [11, 22–25], despite less sensitive ECG-volt-
age LVH criteria being used in these studies. More
recent studies indicate the advantage of time-de-
pendent ECG criteria, such as a prolongation of the
QRSd [26]. Our finding of an independent associa-
tion between LVMIECG, the index entirely based on
time-related measurements, and short-term post-
myocardial infarction outcome seems to support
this observation.
QRSd and post-myocardial infarction
prognosis
The association between QRSd prolongation and
an unfavourable outcome in post-myocardial infarc-
tion patients has been the subject of recent studies
[26–29]. Brilakis et al. [27] showed an independent
association between a QRS prolongation ≥ 100 ms
and in-hospital and overall mortality in patients with
non-ST-elevation MI [26]. Other authors found
a 4-fold greater risk of cardiac death in MI patients with
QRS prolongation ≥ 120 ms. Importantly, in the
Valsartan in Acute Myocardial Infarction (VALIANT)
study, a prolongation of QRSd previously within nor-
mal limits was found to be a marker of increased risk
of cardiovascular death, sudden death and the devel-
opment of heart failure, although this did not pos-
sess independent prognostic value [28]. A recent
analysis of the Danish Investigations and Arrhyth-
mias and Mortality on Dofetilide (DIAMOND) study
indicated that the prognostic value of QRSd is greater
in post-myocardial infarction patients with LV dys-
function than in patients with heart failure. A 10 ms
increase in QRSd was associated with a 6% increased
risk of death over a 10-year period [29].
Accuracy of ECG measurements
Numerical ECG recording opened the opportu-
nity for accurate ECG wave voltage and duration
Table 6. Predictors at 6 months of cardiovascular events (Cox hazard regression)
Parameter Univariate p                        Multivariate*   p
HR 95% CI HR 95% CI
SLV > 3.4 6.7 2.4–18.6 0.0003 – – –
SLVd > 343.7 7.8 2.8–22.3 0.0001 3.7 1.1–12.3 0.0335
CV > 2.2 2.5 0.95–9.8 NS – – –
CVD > 260 4.1 1.5–11.1 0.0058 – – –
12QRSV >1.23 3.7 1.2–11.6 0.0224 – – –
12QRSVD >123 4.5 1.3–15.6 0.0199 – – –
LVMIECG > 115 7.2 2.3–22.5 0.0008 3.9 1.0–15.1 0.0462
*Forward-stepwise regression, – not entered Cox regression model. Age, LVEF and LVEDD did not enter the model; HR — heart rate. Other abbrevia-
tions: see Table 2.
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measurements, and has recently been recommend-
ed [30]. The precision of the QRS determination used
in the present study was far greater than in many pre-
vious studies. In our previous work we documented
the fact that the measurement error for LVMIECG
attained approximately 1.5%, which corresponded to
a value of ~1.8 ms3/m2 [17]. Such a low measurement
error cannot be achieved with the use of a routine
paper speed of 25–50 mm/s and gain of 1 cm/1 mV.
Other findings
Other interesting findings emerged from our
study. Firstly, the authors found that an increased
SLVd product and increased LVMI bore prognostic
information for patients with a relatively preserved
LV function and normal or only moderately pro-
longed QRS complex (< 120 ms). This finding should
be considered significant, as the probability of influ-
ence of intraventricular conduction disturbances on
the results of the study had been minimized by cho-
sen range of the QRS duration. As early coronary in-
terventions limit both myocardial injury and the devel-
opment of significant intraventricular conduction de-
lay, the proportion of patients with a QRSd within the
80–120 range would increase. Therefore distinguish-
ing AMI-patients at higher risk for an unfavourable
outcome among those with a relatively short QRS com-
plex is a challenge, and our proposals help to meet this.
Secondly, in the group of patients with STEMI
examined we were unable to confirm the advantage
of the Cornell LVH criterion, currently commonly
considered as more sensitive and specific for LVH
diagnosis [14]. It has to be borne in mind that this
criterion was developed in quite a different popula-
tion of patients (those with hypertension) and for
different purposes (mainly epidemiological) and, as
far as the authors know [16], the Cornell University
criterion has never been verified in patients with
STEMI. Despite a somewhat greater concordance
between an echocardiographically-determined in-
creased LVM and the Cornell LVH criterion, the lat-
ter was not demonstrated be an independent risk
predictor in our group of STEMI patients. One of the
possible explanations is that the presence of myo-
cardial scar reflected by the Q-wave appearance in
the precordial V1–V3 leads might provide an errone-
ous calculation of SLV or the Cornell LVH index.
Interestingly, a discrepancy between LVH detec-
tion and the correlation with the LVMI was found for
several commonly used voltage-dependent ECG
LVH-criteria. As the determinants of the QRS volt-
age on the surface ECG are different and more im-
portant than upon echocardiogram, a voltage-inde-
pendent ECG index, such as LVMIECG, seems to be
more promising, as indicated by the most significant,
although still only moderate, correlation with LVMIECHO.
Limitations
The authors are aware that exclusion criteria can
weaken the significance of findings and so the ob-
servations made and conclusion drawn cannot be
extrapolated into the entire PCI-treated STEMI pop-
ulation. Furthermore, the cut-off values used should
not be treated as limit values for LVH diagnosis, as
they were chosen on the basis of ROC curve analy-
sis with respect to the occurrence of an unfavoura-
ble outcome rather than LVH itself, despite these
values lying within close proximity to the accepted
ones [14]. We also kept in mind that echocardiogra-
phy cannot be further considered as the “gold stand-
ard” for LVM determination in an era of ever more
sophisticated and accurate methods such as nuclear
magnetic resonance [31]. Nevertheless its use in this
study was justified by the general application of
echocardiography in clinical settings. Lastly, use of
the QRSd-dependent index as a surrogate of LVM
has its own limits related to the presence of ischemia
and fibrosis, especially in the AMI setting. Howev-
er, these two processes, both known to prolong and
disturb the intraventricular conduction, are them-
selves important features of LVH and are initiated
well before LVM increases enough to be diagnosed
by means of echocardiography.
Conclusion
In an era of interventional treatment of acute
myocardial infarction, the ECG features of left ven-
tricular hypertrophy carry independent significant
prognostic information.
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